ADMS - Adamas Pharmaceuticals, Inc.
| Previous Close | 8.67 |
| Open | 8.71 |
| Bid | 0.00 x 2900 |
| Ask | 0.00 x 900 |
| Day's Range | 8.48 - 8.88 |
| 52 Week Range | 7.42 - 44.00 |
| Volume | 268,440 |
| Avg. Volume | 689,262 |
| Market Cap | 235.359M |
| Beta (3Y Monthly) | 2.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.10 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.60 |
- GlobeNewswire•13 days ago
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 35,366 shares of the company’s common stock, at a per share exercise price of $9.56, the closing trading price on January 8, 2019, and restricted stock units to acquire 5,910 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- Motley Fool•14 days ago
Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
- GlobeNewswire•18 days ago
Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today outlined key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI™ (amantadine) extended release capsules. GOCOVRI is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy and only medication clinically proven to reduce both dyskinesia and OFF in that population.
- Benzinga•last month
The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week highs Tuesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 18) Accelerate ...
- GlobeNewswire•last month
Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™
The USPTO has now issued a total of 14 patents from three separate patent families in the GOCOVRI patent portfolio, which now has patents expiring from 2025 to 2034. The ‘971 patent will be listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. GOCOVRI (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
- Insider Monkey•last month
Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. […]
- Motley Fool•last month
Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November
Adamas Pharmaceuticals' valuation took yet another hit last month. Here's why.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT
Q3 2018 Adamas Pharmaceuticals Inc Earnings Call
- GlobeNewswire•2 months ago
Adamas to Present at Three November Investor Conferences
EMERYVILLE, Calif., Nov. 09, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central.
- GlobeNewswire•3 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Apptio, Adamas Pharmaceuticals, NEXEO SOLUTIONS, Computer Programs and, Solaris Oilfield Infrastructure, and SPX — New Research Emphasizes Economic Growth
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Motley Fool•3 months ago
The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today
Shares fall hard after the company reports good news. What's going on?
- Associated Press•3 months ago
Adamas: 3Q Earnings Snapshot
The Emeryville, California-based company said it had a loss of $1.22 per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was ...
- GlobeNewswire•3 months ago
Adamas Reports Third Quarter 2018 Financial Results
GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018.
- Benzinga•3 months ago
The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Merck & Co., Inc. (NYSE: MRK )(announced FDA approval ...
- GlobeNewswire•3 months ago
Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that it will report third quarter 2018 financial results on Thursday, November 1, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers.
- Reuters•3 months ago
China cutting rare earth output, unnerving global manufacturers
LONDON/HOUSTON Oct 24 (Reuters) - The Chinese government is limiting domestic production of rare earth minerals in the second half of the year, a move likely to crimp international exports and send prices for the critical materials soaring, according to data from Adamas Intelligence. China is by far the world's largest producer and consumer of rare earths, a group of 17 elements used to make electric vehicles and consumer electronics. The move is already forcing manufacturers to scour the globe for alternative supplies.
- Motley Fool•3 months ago
Why Adamas Pharmaceuticals, Inc. Stock Sank in September
Adamas' steady march lower continued in September. Here's why.
- Simply Wall St.•4 months ago
When Can We Expect A Profit From Adamas Pharmaceuticals Inc (NASDAQ:ADMS)?
Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS): Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The US$543m market-cap posted a loss in its most recent financial year of -US$89m Read More...
Market Realist•4 months agoA Financial Overview of Supernus Pharmaceuticals in September
In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.
Market Realist•4 months agoSupernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.
